Cortexyme Announces Key Leadership Appointments to Support Next Stage of Growth

FLG client, Cortexyme, a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative disorders, announced effective January 2019, two key leadership appointments. Veteran clinical development professional Michael Detke, M.D., Ph.D., has been appointed Chief Medical Officer and Chris Lowe, a longtime…Read More

Read More
Soleno Therapeutics Announces $16.5 Million Private Placement

REDWOOD CITY, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) — FLG client, Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has entered into a definitive agreement with certain institutional and accredited investors to raise aggregate gross proceeds…Read More

Read More
Rothy’s Announces Revenues of $140 Million

FLG Partner’s consumer client, Rothy’s, where Stephanie Roberts is CFO, is expected to post revenues of $140 million according to a recent article from Bloomberg. In U.S. sales, Rothy’s has quickly eclipsed Tod’s ($88 million in North America last year), and now measures about a third of the size of the Crocs empire of…Read More

Read More
Coinbase Valuation Leaps to $8 Billion After $300 Million Round Closes

FLG Partner’s client Coinbase  reports it is now valued at over $8 billion after closing a new $300 million round of funding to “accelerate the adoption of cryptocurrencies and digital assets.” FLG’s Tim Laehy was instrumental as Coinbase’s CFO during their high growth years in 2017 and 2018. The Series…Read More

Read More
Oyster Point Announces Positive Results From Phase 2b Clinical Trials for Dry Eye Disease

PRINCETON, N.J.–(BUSINESS WIRE)–October 24, 2018 – Oyster Point Pharma, Inc., today announced results from the ONSET and RAINIER studies, two separate Phase 2b clinical trials evaluating the company’s novel therapies for the treatment of Dry Eye Disease (DED). Both studies, being presented tomorrow at the Ophthalmology Innovation Summit (OIS) meeting…Read More

Read More